Back to top
more

Annovis Bio (ANVS)

(Delayed Data from NYSE)

$12.16 USD

12.16
982,250

-0.95 (-7.25%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $12.49 +0.33 (2.71%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001

by Zacks Equity Research

Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication.

Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review

by Zacks Equity Research

Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full approval gets accepted by the FDA.

Pieris (PIRS) Up On Receiving Milestone Payment From Partner

by Zacks Equity Research

Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.

Wall Street Analysts See a 213.78% Upside in Annovis Bio, Inc. (ANVS): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 213.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs

by Zacks Equity Research

Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.

Best Momentum Stocks to Buy for April 21st

by Zacks Equity Research

ANVS, ACLX and WOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 21, 2023.

New Strong Buy Stocks for April 21st

by Zacks Equity Research

WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.

Best Momentum Stocks to Buy for April 18th

by Zacks Equity Research

VRCA, BZ and ANVS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 87, 2023.

Wall Street Analysts Think Annovis Bio, Inc. (ANVS) Could Surge 190.96%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 191% upside potential for Annovis Bio, Inc. (ANVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

New Strong Buy Stocks for April 18th

by Zacks Equity Research

EGY, ANVS, HCC, MPC and ANDE have been added to the Zacks Rank #1 (Strong Buy) List on April 18, 2023.

Annovis Bio, Inc. (ANVS) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Annovis Bio, Inc. (ANVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Avidity (RNA) Down on Update From Neuromuscular Disease Study

by Zacks Equity Research

Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.

Here's Why Momentum in Annovis Bio, Inc. (ANVS) Should Keep going

by Zacks Equity Research

Annovis Bio, Inc. (ANVS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.

Bicycle (BCYC) up on Collaboration With Novartis for Conjugates

by Zacks Equity Research

Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.

Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug

by Zacks Equity Research

Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.

Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?

by Zacks Equity Research

Here is how Annovis Bio, Inc. (ANVS) and Aptose Biosciences (APTO) have performed compared to their sector so far this year.

Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up

by Zacks Equity Research

Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.

COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar

by Zacks Equity Research

COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.

Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead

by Zacks Equity Research

Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.

Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use

by Zacks Equity Research

The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response.

Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.

Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up

by Zacks Equity Research

Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.

Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome

by Zacks Equity Research

Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.